Premium
Novel bivalent vectored vaccine for control of myxomatosis and rabbit haemorrhagic disease
Author(s) -
Spibey N.,
McCabe V. J.,
Greenwood N. M.,
Jack S. C.,
Sutton D.,
Waart L.
Publication year - 2012
Publication title -
veterinary record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 99
eISSN - 2042-7670
pISSN - 0042-4900
DOI - 10.1136/vr.100366
Subject(s) - bivalent (engine) , myxomatosis , virology , disease control , biology , veterinary medicine , medicine , virus , chemistry , organic chemistry , metal
A novel, recombinant myxoma virus‐rabbit haemorrhagic disease virus (RHDV) vaccine has been developed for the prevention of myxomatosis and rabbit haemorrhagic disease (RHD). A number of laboratory studies are described illustrating the safety and efficacy of the vaccine following subcutaneous administration in laboratory rabbits from four weeks of age onwards. In these studies, both vaccinated and unvaccinated control rabbits were challenged using pathogenic strains of RHD and myxoma viruses, and 100 per cent of the vaccinated rabbits were protected against both myxomatosis and RHD.